• Publications
  • Influence
Integrative genomic profiling of human prostate cancer.
TLDR
Analysis of genomic and clinical outcome data from 218 prostate cancer tumors revealed that copy-number alterations robustly define clusters of low- and high-risk disease beyond that achieved by Gleason score. Expand
Integrative Clinical Genomics of Advanced Prostate Cancer
TLDR
This cohort study provides clinically actionable information that could impact treatment decisions for affected individuals and identified new genomic alterations in PIK3CA/B, R-spondin, BRAF/RAF1, APC, β-catenin, and ZBTB16/PLZF. Expand
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer
TLDR
An analysis of 412 muscle-invasive bladder cancers characterized by multiple TCGA analytical platforms identified 5 expression subtypes that may stratify response to different treatments and identified a poor-survival "neuronal" subtype in which the majority of tumors lacked small cell or neuroendocrine histology. Expand
Aberrant Nuclear Immunoreactivity for TFE3 in Neoplasms With TFE3 Gene Fusions: A Sensitive and Specific Immunohistochemical Assay
TLDR
The finding in the set of test cases that morphologic features can be used to predict TFE3 immunoreactivity further supports the notion that renal carcinomas with T FE3 gene fusions have a distinctive morphology that corresponds to their genetic distinctiveness. Expand
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.
TLDR
Type 1 and type 2 papillary renal-cell carcinomas were shown to be different types of renal cancer characterized by specific genetic alterations, with type 2 further classified into three individual subgroups on the basis of molecular differences associated with patient survival. Expand
The Molecular Taxonomy of Primary Prostate Cancer
TLDR
A comprehensive molecular analysis of 333 primary prostate carcinomas revealed a molecular taxonomy in which 74% of these tumors fell into one of seven subtypes defined by specific gene fusions (ERG, ETV1/4, and FLI1) or mutations (SPOP, FOXA1, and IDH1). Expand
The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours.
TLDR
This review summarizes the most significant differences between the newly published classification of urogenital tumours and the prior version for renal, penile, and testicular tumours. Expand
A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score.
TLDR
Looking at outcomes for prostate cancer treated with radical prostatectomy or radiation therapy and validated a new grading system with more accurate grade stratification than current systems, including a simplified grading system of five grades and the lowest grade is 1, as opposed to 6, with the potential to reduce overtreatment of PCa. Expand
Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.
TLDR
Treatment with novel agents during a clinical trial is indicated for patients with metastatic RCC after progression to cytokine treatment, and three prognostic factors for predicting survival were used to categorize patients into risk groups. Expand
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer
TLDR
It is concluded that determination of ERG gene status, including duplication of the fusion of TMPRSS2 to ERG sequences in 2+Edel, allows stratification of prostate cancer into distinct survival categories. Expand
...
1
2
3
4
5
...